Ecolab Inc. (ECL) — Q2 2026 Earnings Preview

Earnings Preview

Key Takeaway: Setup is constructive — consensus is a manageable bar after the Q2 ‘transition quarter’ framing was well-telegraphed, and the mid-quarter guidance raise at William Blair signals the energy surcharge is executing ahead of plan; the biggest swing factor is whether organic gross margin stabilization materializes as promised.

Heading into Q2 2026, the bar for Ecolab is deliberately set low: management pre-framed Q2 as a “short transition quarter” on the April 28 earnings call, guiding adjusted EPS growth of 7–12% versus the full-year 12–15% target, and consensus has aligned accordingly at ~$2.08 adjusted EPS. Critically, management raised the low end of Q2 EPS growth guidance to 9–12% at the William Blair Growth Stock Conference on June 2 — more than halfway through the quarter — citing strong energy surcharge execution and continued business momentum, which meaningfully de-risks the print.

Estimate trajectory has been stable-to-slightly-positive since the Q1 print, with the Q2 consensus EPS estimate essentially unchanged from the post-earnings baseline (~$2.08), suggesting the street has already absorbed the transition-quarter narrative without further downward drift.

The stock has underperformed XLB and the S&P 500 since the April 28 print (ECL indexed ~101 vs. SPY ~104 as of July 28), meaning the stock has not priced in a beat, and the valuation at ~28x forward earnings is not stretched relative to ECL’s historical premium.

The key wildcard is the CoolIT acquisition close on July 2 (earlier than expected, $4.75B), which updated full-year EPS guidance to $8.03–$8.23 (7–9% growth including ~$0.20/quarter dilution in H2) — the market’s reaction to how management frames the CoolIT integration trajectory and the H2 organic gross margin recovery story will likely determine whether the stock re-rates on this print.

KPIs & Consensus Expectations

Key Takeaway: Consensus is a low-to-manageable bar after the transition-quarter framing; adjusted EPS ($2.08 consensus vs. $1.89 prior year) and organic operating margin are the two biggest swing factors — any upside surprise on gross margin stabilization or organic sales growth above 4% would be the key positive catalyst.

Table 1 — Q2 2026 Current Quarter Snapshot

Sources: Visible Alpha Consensus and Actuals Data; ECL Q1 2026 Earnings Call (April 28, 2026); William Blair Growth Stock Conference (June 2, 2026). Adjusted EPS Q1 2026 actual: $1.70; Q2 2025 actual: $1.89; Q2 2026 consensus: $2.08. Net Sales Q1 2026 actual: $4.07B; Q2 2025 actual: $4.03B; Q2 2026 consensus: $4.37B. Adj. Operating Income Q1 2026 actual: $679.7M; Q2 2025 actual: $737.2M; Q2 2026 consensus: $819.4M. Adj. Operating Margin Q1 2026 actual: 16.7%; Q2 2025 actual: 18.3%; Q2 2026 consensus: 18.7%. Adj. Gross Margin Q1 2026 actual: 43.8%; Q2 2025 actual: 44.8%; Q2 2026 consensus: 44.1%.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

Top 2 KPIs: Adjusted Diluted EPS and Organic Sales Growth (%)

Pattern: ECL has a strong track record of meeting or beating adjusted EPS (beat or in-line in 7 of the last 8 quarters), but organic sales growth has been the more volatile KPI — missing consensus in 5 of the last 8 quarters, reflecting the street’s tendency to over-estimate volume acceleration. The Q2 2026 organic growth consensus of ~4.8% is above the Q1 actual of 4.0%, which sets a modestly higher bar on the top line.

Source: Visible Alpha Consensus and Actuals Data.

Guidance & Commentary Evolution

Key Takeaway: Management raised the low end of Q2 EPS growth guidance mid-quarter at William Blair (June 2), signaling strong surcharge execution; full-year guidance was formally updated on July 2 to incorporate CoolIT dilution, but the underlying base business trajectory is unchanged at 12–15% EPS growth.

Sources: ECL Q1 2026 Earnings Call (April 28, 2026); William Blair Growth Stock Conference (June 2, 2026); Ecolab CoolIT Acquisition Close Press Release (July 2, 2026); Visible Alpha Consensus Data.

Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates for Q2 2026 EPS have been essentially flat since the Q1 print (post-earnings baseline ~$2.08, current ~$2.08), suggesting the street fully absorbed the transition-quarter framing without further cuts; FY 2026 EPS estimates have drifted slightly lower post-CoolIT dilution disclosure, but the base business trajectory is intact.

The FY 2026 EPS estimate decline of ~2.5% since the Q1 print is entirely explained by the CoolIT acquisition dilution (~$0.40 in H2 2026), not by any deterioration in the base business. The Q2 2026 EPS estimate has been remarkably stable, consistent with management’s mid-quarter confidence signal at William Blair. FY 2027 estimates have drifted slightly lower as analysts model CoolIT integration costs, but management has explicitly guided for the dilution to neutralize in 2027 as Nalco amortization rolls off.

Source: Visible Alpha Consensus and Actuals Data (as-of date May 5, 2026 for baseline; current as of July 27, 2026). Adj. EPS Q2 2026 baseline: $2.08; current: $2.08. Net Sales Q2 2026 baseline: $4.37B; current: $4.37B. Adj. EPS FY 2026 baseline: $8.40; current: $8.19. Net Sales FY 2026 baseline: $17.65B; current: $17.81B. Adj. EPS FY 2027 baseline: $9.65; current: $9.40.

Stock Performance

Key Takeaway: ECL has essentially tracked flat since the April 28 earnings print (indexed ~101 vs. SPY ~104 and XLB ~99), underperforming the S&P 500 but outperforming materials peers; the stock has not priced in a beat, leaving room for upside if Q2 execution and H2 guidance impress.

ECL vs. XLB vs. S&P 500 — Indexed Performance Since Q1 2026 Earnings (April 28, 2026). Base = 100. Source: Yahoo Finance / Stock Price Data.

ECL opened at $267.88 on April 27 (day before earnings) and closed at $271.38 on July 28 (earnings day), a gain of ~1.3% in absolute terms. Over the same period, SPY gained ~3.3% and XLB declined ~0.8%. ECL’s modest underperformance vs. the S&P 500 reflects the market’s wait-and-see posture on the Q2 transition quarter and CoolIT dilution, rather than any fundamental deterioration. The stock dipped sharply on April 29 (day after earnings, -3.9%) as the market digested the Q2 transition framing, then recovered steadily through June and July as the William Blair guidance raise and CoolIT close provided positive catalysts. The stock is trading at approximately 28x forward earnings, a modest premium to its 5-year average of ~26x, reflecting confidence in the 12–15% EPS growth trajectory but not yet pricing in a re-rating from the growth engine mix shift.

Key events marked: April 28 — Q1 2026 Earnings (in-line EPS, above-consensus revenue, Q2 transition framing); June 2 — William Blair Conference (Q2 guidance low end raised to 9–12%); July 2 — CoolIT acquisition close ($4.75B, FY 2026 EPS guidance updated to $8.03–$8.23).

Material News & Developments

Key Takeaway: The CoolIT acquisition close (July 2, $4.75B) is the most consequential development since Q1 earnings — it formally transforms ECL’s Global High-Tech business into a ~$1.5B revenue platform targeting $4B by 2030, but introduces ~$0.40 of H2 2026 EPS dilution that the market must weigh against the long-term growth optionality.

• July 2, 2026 — CoolIT Acquisition Closes ($4.75B, Earlier Than Expected): Ecolab closed its acquisition of CoolIT Systems, a leader in direct liquid cooling for high-density data centers, for $4.75B — ahead of the originally expected Q3 2026 close. Combined with Ovivo, ECL’s Global High-Tech business now approaches $1.5B in annualized sales (up from ~$150M in 2021). Management targets $4B in Global High-Tech sales by 2030 at 25% operating margins. Implication: Accelerates the AI/data center growth narrative but introduces ~$0.20/quarter EPS dilution in H2 2026 from non-cash amortization and financing costs; 2027 expected to neutralize as Nalco amortization rolls off.
• July 2, 2026 — FY 2026 EPS Guidance Updated to $8.03–$8.23 (7–9% Growth): Reflecting CoolIT dilution, full-year adjusted EPS guidance was revised from the prior 12–15% growth framework (excl. CoolIT) to $8.03–$8.23 total. H2 2026 base business EPS growth remains 14–15%; CoolIT reduces reported H2 growth to 4–5%. Implication: The headline EPS growth rate will look optically weak in H2 2026; investors need to focus on the base business trajectory and CoolIT’s revenue ramp.
• June 2, 2026 — William Blair Growth Stock Conference (Q2 Guidance Raised Mid-Quarter): Management raised the low end of Q2 2026 EPS growth guidance from 7–12% to 9–12%, citing strong energy surcharge execution with >50% of Q2 complete. Organic sales growth floor raised to ≥44%. Stable organic gross margins (ex-Ovivo) guided. Implication: Strongest positive signal heading into the print — management rarely raises guidance mid-quarter unless execution is tracking well above the low end.
• May 11, 2026 — Bryce Mewhorter Named Corporate Controller / Principal Accounting Officer: Routine leadership appointment (8-K filing). No material financial implications.
• April 28, 2026 — Q1 2026 Earnings: Energy Surcharge Implemented April 1: ECL implemented an energy surcharge across 100% of customers, businesses, and countries starting April 1 to offset high-single-digit commodity cost inflation. Q2 framed as a ‘short transition quarter.’ Implication: The surcharge execution is the key variable for Q2 gross margin; William Blair commentary suggests it is tracking ahead of plan.
• Analyst Ratings: Moderate Buy Consensus, Average PT ~$323: 21 analysts cover ECL with a Moderate Buy consensus (18 Buy, 3 Hold, 0 Sell). Price targets range from $275 (Wells Fargo, Hold) to $345 (Jefferies, Buy). UBS upgraded to Buy with a $325 PT on May 27. Berenberg maintained Buy at $299 on May 28. Wells Fargo maintained Hold at $275 on June 10. Implication: Broad bullish consensus with limited downside risk from ratings; the stock trades at a ~15% discount to the average PT, suggesting room for re-rating on a strong print.
• Macro: Middle East Conflict Driving Energy Cost Inflation: Management cited the Middle East conflict as a driver of sharply higher global energy costs, with commodity costs up ~9% in Q1 and expected to remain elevated through year-end. The energy surcharge is ECL’s primary offset mechanism. Implication: If energy costs moderate faster than expected, ECL could see upside to gross margins in H2 2026.

Peer Commentaries — Q2 2026 Read-Throughs (Last 60 Days)

Key Takeaway: Peer commentary from Q2 2026 earnings calls (Thermo Fisher, Danaher, Agilent, IFF) and RPM’s Q4 FY2026 call collectively paint a constructive picture for ECL’s key end markets — bioprocessing/Life Sciences demand is accelerating, institutional/food & beverage customers are healthy, and energy surcharge execution is a shared industry theme with peers confirming the pricing recovery playbook works.

Note: Only commentary from peers reporting on or after April 28, 2026 (ECL’s last earnings date) about current-quarter (Q2 2026 calendar) trends is included. Prior-quarter result discussions are excluded.

Thermo Fisher Scientific (TMO) — Q2 2026 Earnings Call (July 23, 2026)

Read-Through Relevance: ECL’s Life Sciences segment (~$1B revenue, growing double-digits with bioprocessing more than doubling in Q1) is a direct beneficiary of the same biopharma/biotech spending trends TMO reports on.

• Bioprocessing demand accelerating into Q2: TMO reported its Life Sciences Solutions segment grew 13% reported / 3% organic in Q2, led by its Bioproduction business which “had another quarter of excellent organic growth.” Upstream consumables grew strong double-digits. ECL read-through: Positive for ECL’s Life Sciences bioprocessing business, which accelerated to 11% growth in Q1 with bioprocessing more than doubling. TMO’s data confirms the underlying demand environment remains robust.
• Pharma & biotech spending picking up: TMO noted “good momentum continues in pharma, but also biotech. Clearly, we saw spending pick up” in Q2. Biotech activity has been picking up for several quarters in authorizations, with a ~6-month lag to revenue. Large pharma customers show “quite a positive tone” with excitement about pipelines. ECL read-through: Supports ECL’s expectation of continued double-digit Life Sciences growth momentum and validates the bioprocessing acceleration narrative.
• Full-year guidance raised: TMO raised full-year organic revenue growth guidance to ~4% (upper end of 3–4% range) and raised adjusted EPS guidance to $24.93–$25.33 (9–11% growth). H2 improvement primarily driven by pharma and biotech. ECL read-through: Confirms the biopharma end market is strengthening into H2 2026, which is a tailwind for ECL’s Life Sciences segment growth acceleration.
• Filtration/separation capacity being added: TMO noted its filtration and separation business is “doing very well and demand has been strong” with capacity being increased. ECL read-through: Positive for ECL’s Global High-Tech water treatment business serving semiconductor fabs and data centers, which requires ultra-pure water and filtration solutions.

Danaher (DHR) — Q2 2026 Earnings Call (July 21, 2026)

Read-Through Relevance: DHR’s Cytiva bioprocessing franchise is the closest direct read-through to ECL’s Life Sciences segment; DHR’s microelectronics/semiconductor commentary also reads through to ECL’s Global High-Tech business.

• Bioprocessing order trends robust despite revenue timing noise: DHR reported bioprocessing grew low single digits in Q2, with consumables below expectations due to large chromatography resin shipments moving out of the quarter (customer-driven timing). However, underlying demand was “very healthy” with mid-teens order growth in both consumables and equipment. ECL read-through: The timing noise at DHR is specific to large batch chromatography resins — not relevant to ECL’s Life Sciences mix. The mid-teens order growth signal is a strong positive read-through for ECL’s bioprocessing demand.
• Equipment growth signals multi-year CapEx cycle: DHR saw equipment growth in Q2 for the first time in several quarters, driven by customer investments in manufacturing capacity (reshoring, brownfield expansion). Management stated: “we continue to believe that we’re in the early innings here of a multi-year CapEx cycle.” ECL read-through: Positive for ECL’s Global High-Tech business (fab expansions, data center builds) and Life Sciences (biopharma manufacturing capacity build-out).
• Microelectronics/semiconductor strength: Pall’s applied filtration business grew ~10%, led by strength in microelectronics (semiconductors and memory customers). ECL read-through: Direct positive read-through for ECL’s Global High-Tech water treatment business serving semiconductor fabs; Ovivo’s ultra-pure water business is growing at mid-teens rates.
• Biotech funding translating to orders: DHR noted biotech funding is “starting to play through” from funnel to orders and “on the margins, we’re starting to see some revenue.” ECL read-through: Supports ECL’s Life Sciences growth acceleration thesis; biotech funding recovery is a multi-quarter tailwind.

Agilent Technologies (A) — Q2 FY2026 Earnings Call (May 27, 2026)

Read-Through Relevance: Agilent’s pharma/biotech end market commentary and GLP-1 momentum read through to ECL’s Life Sciences segment; Agilent’s pricing execution (200 bps in Q2) validates ECL’s value-pricing model.

• Pharma growing 6% for fifth consecutive quarter: Agilent reported pharma grew 6% in Q2 FY2026, marking the fifth consecutive quarter of mid-single-digit to low double-digit growth. Biotech grew low double digits for the third consecutive quarter, led by large-cap companies. ECL read-through: Confirms the pharma/biotech end market is in a sustained recovery, supporting ECL’s Life Sciences double-digit growth trajectory.
• GLP-1 momentum delivering ~20% growth YTD: Agilent’s GLP-1 business delivered approximately 20% growth year-to-date. Large pharma customers are planning to reshore operations to the U.S. ECL read-through: GLP-1 manufacturing scale-up requires significant water treatment and hygiene solutions — a potential incremental tailwind for ECL’s Life Sciences and Food & Beverage segments.
• Strategic pricing delivering 200 bps in Q2: Agilent’s strategic pricing capability delivered approximately 200 basis points of pricing in Q2, exceeding its full-year goal of 100 bps. ECL read-through: Validates ECL’s value-pricing model; if Agilent can achieve 200 bps of pricing in a competitive life sciences tools market, ECL’s 3% structural pricing target (plus energy surcharge) appears achievable.
• Full-year guidance raised; H2 confidence despite tougher comps: Agilent raised full-year core growth guidance to 4.5–6% and EPS guidance to $6.00–$6.10. Management cited execution excellence, market momentum, and structural improvements as drivers of H2 confidence. ECL read-through: Positive sentiment for the broader life sciences and specialty chemicals end market heading into H2 2026.

IFF (International Flavors & Fragrances) — Q1 2026 Earnings Call (May 6, 2026)

Read-Through Relevance: IFF serves many of the same food & beverage and institutional customers as ECL; its energy surcharge implementation and commodity cost management commentary is a direct read-through to ECL’s Q2 transition quarter narrative.

• Energy surcharge implementation underway, building through Q2: IFF noted its energy surcharges related to logistics and energy costs are “currently underway and expected to build throughout the quarter.” CFO DeVeau stated: “consistent with historical inflationary cycles, we collaborate with our customers to fully offset any inflation. And usually, it’s a 12- to 18-month period.” ECL read-through: IFF’s 12–18 month recovery timeline contrasts sharply with ECL’s guided “within one quarter” recovery — highlighting ECL’s superior pricing power and customer value delivery model. ECL’s faster recovery is a competitive differentiator.
• Q2 EBITDA expected lower due to price-cost lag: IFF guided Q2 absolute EBITDA dollars below Q1’s $568M, driven by “unfavorability in terms of price to input cost” as surcharges are not yet fully implemented. Post-Q2, all three headwinds (volume, price-cost, mix) are expected to improve. ECL read-through: IFF’s Q2 margin pressure from the same commodity/energy inflation validates ECL’s transition quarter framing; ECL’s faster surcharge execution (raised guidance mid-quarter) suggests ECL is outperforming peers on pricing recovery speed.
• Volume growth solid across all segments in Q1: IFF delivered 3% sales growth in Q1 driven by volume improvements across all businesses, with Health & Biosciences leading at mid-single-digit growth. Food Ingredients volume growth was ~5%, “the highest it has been in several years.” ECL read-through: Healthy food & beverage end market demand supports ECL’s Food & Beverage segment (guided 6–8% growth in 2026) and Institutional segment.
• Middle East conflict impacting Fine Fragrance but not core businesses: IFF noted Middle East conflict is impacting Fine Fragrance volumes in Q2 but core food & beverage and health businesses remain solid. ECL read-through: ECL management noted Middle East is a “pretty small business” for ECL; the broader food & beverage and institutional demand environment appears healthy.

RPM International — Q4 FY2026 Earnings Call (July 22, 2026)

Read-Through Relevance: RPM serves many of the same industrial, institutional, and food & beverage end markets as ECL; its commodity cost inflation and pricing recovery commentary is a relevant read-through for ECL’s energy surcharge execution and gross margin trajectory.

• Pricing recovery tracking dollar-for-dollar on commodity inflation: RPM noted price was up ~2% in Q4 FY2026 and the company “generally has been successful in recovering price on a dollar-for-dollar basis” during high inflationary periods, retaining 100% of price increases due to brand strength. ECL read-through: Validates ECL’s pricing recovery model; ECL’s energy surcharge is designed to achieve the same dollar-for-dollar offset, and management’s mid-quarter confidence signal suggests it is tracking well.
• Raw material inflation 5–6% in Q1 FY2027, potentially 6–8% in Q2: RPM guided raw material inflation of 5–6% in Q1 FY2027 (calendar Q3 2026) and potentially 6–8% in Q2 FY2027, with price-cost expected to be “somewhat negative in the first half” before becoming “more neutral in the back half.” ECL read-through: Suggests commodity cost inflation may persist longer than ECL’s base case; however, ECL’s surcharge-to-structural-pricing conversion strategy is designed to handle sustained inflation. If RPM’s inflation trajectory materializes, ECL’s H2 gross margin recovery could be more gradual than guided.
• Data center demand ‘even keel’ at 1–2% of RPM revenue: RPM noted data center activity is “even keel” and represents ~1–2% of total revenue, with Euclid Chemical having the largest exposure. ECL read-through: ECL’s Global High-Tech data center exposure is far larger and growing faster (approaching $1.5B with CoolIT); RPM’s ‘even keel’ comment on data center activity is not a negative signal for ECL’s liquid cooling business, which serves a different part of the value chain.
• Institutional/commercial construction remains weak; maintenance & restoration strong: RPM noted underlying commercial construction is “weak” but maintenance and restoration demand across hospital systems, schools, and manufacturing is solid. ECL read-through: ECL’s Institutional segment (hotels, restaurants, healthcare) is more tied to maintenance/hygiene spend than new construction — RPM’s commentary on institutional maintenance demand is a mild positive read-through.

Sources: Thermo Fisher Scientific Q2 2026 Earnings Call (July 23, 2026); Danaher Q2 2026 Earnings Call (July 21, 2026); Agilent Technologies Q2 FY2026 Earnings Call (May 27, 2026); IFF Q1 2026 Earnings Call (May 6, 2026); RPM International Q4 FY2026 Earnings Call (July 22, 2026).

Insider Transaction Activity

Key Takeaway: Two notable open-market purchases stand out — Director David MacLennan bought 1,800 shares (~$450K) across two transactions in early May, and Director Michel Doukeris purchased 7,750 shares (~$2M) on June 10 — both at prices well below current levels, signaling board-level conviction. No open-market sales by executives.

Open-market buys (Form 4 code P) and sells (code S) only. Routine equity award grants (code A), RSU vesting/tax withholding (codes M/F), and option exercises are noted separately.

Summary: The insider picture is constructive. Three open-market purchases by two directors (MacLennan: 1,800 shares total in early May; Doukeris: 7,750 shares on June 10) and one executive (Clark: 1,000 shares on June 11) represent meaningful discretionary buying at prices in the $255–$265 range — well below the current ~$271 level. Doukeris’ ~$2M purchase is particularly notable given its size. The only sales in the period are obligation-driven (tax withholding on RSU vesting, option exercise-and-sell) and carry no negative signal. No 10b5-1 plan initiations were filed in the period. The absence of any discretionary selling by executives heading into earnings is a mild positive signal.

Source: SEC Form 4 filings via Insider Transaction Data.